CLEC9A-based chimeric protein complexes
US12351614B2 · kind B2 · utility
0Cited by
26References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 27, 2020 |
| Grant date | Jul 8, 2025 |
| Priority date | — |
| Expiry date | Mar 27, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates, in part, to chimeric protein complexes including an anti-Clec9A targeting moiety, a modified Fc domain, and a modified human IFNα and their use as therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the chimeric protein complexes and their use in the treatment of various diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.